{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:41:38Z","timestamp":1794490898987,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06757"],"award-info":[{"award-number":["22K06757"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06225"],"award-info":[{"award-number":["23K06225"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Edoxaban is used as an anti-coagulant to prevent cardioembolic infarction, deep vein thrombosis, and pulmonary embolism. Edoxaban pharmacokinetics have been reported to be affected by several factors such as renal function, age, body weight, and the concomitant use of P-glycoprotein inhibitors. However, the relationship between genetic polymorphisms in drug metabolizing enzymes and transporters and the inter-individual variability of edoxaban pharmacokinetics in patients with atrial fibrillation (AF) remains unclear. Additionally, there is little information concerning PPK analysis using real world data. In this study a population pharmacokinetic and pharmacogenomic analysis was conducted to clarify covariate factors affecting the edoxaban pharmacokinetics in Japanese adult AF patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>One hundred and thirty-one blood samples were collected from 131 patients. The edoxaban pharmacokinetic profile was described by a one-compartment model, and pharmacogenomic data were stratified according to <jats:italic>CYP3A5<\/jats:italic> (<jats:italic>CYP3A5<\/jats:italic>*3) and <jats:italic>ABCB1<\/jats:italic> (<jats:italic>ABCB1<\/jats:italic> 1236\u00a0C\u2009&gt;\u2009T, 2677G\u2009&gt;\u2009T\/A, and 3435\u00a0C\u2009&gt;\u2009T) polymorphisms. A non-linear mixed-effects modeling software (NONMEM\u2122) was used to evaluate the effects of patient characteristics and genetic polymorphisms on the edoxaban pharmacokinetics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The apparent oral clearance (CL\/F) of edoxaban was estimated, and the apparent volume of distribution was fixed at the reported value. The CL\/F of edoxaban was correlated non-linearly with creatinine clearance (CLcr), wherein the population mean CL\/F for a typical patient (CLcr\u2009=\u200961.8 mL\/min) was estimated to be 28.2\u00a0L\/h. Other clinical laboratory data and genetic polymorphisms, excluding CLcr, did not affect the edoxaban pharmacokinetics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These results suggest that genetic polymorphisms of <jats:italic>CYP3A5<\/jats:italic> and <jats:italic>ABCB1<\/jats:italic> are not considered intrinsic factors affecting edoxaban pharmacokinetics in Japanese adult AF patients. Similarly to previous studies, renal function affects its pharmacokinetics. These findings may provide useful information for individualized anticoagulant therapy with edoxaban to prevent adverse events without reference to genetic polymorphisms of <jats:italic>CYP3A5<\/jats:italic> and <jats:italic>ABCB1<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00453-2","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:16:55Z","timestamp":1748863015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population pharmacokinetics and pharmacogenomics of edoxaban in Japanese adults with atrial fibrillation"],"prefix":"10.1186","volume":"11","author":[{"given":"Satoshi","family":"Ueshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Hira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayana","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rio","family":"Michihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritake","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Kashiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Katsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"453_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1161\/CIRCRESAHA.116.308407","volume":"120","author":"H Kamel","year":"2017","unstructured":"Kamel H, Healey JS. Cardioembolic stroke. Circ Res. 2017;120:514\u201326. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308407.","journal-title":"Circ Res"},{"key":"453_CR2","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1212\/01.wnl.0000216132.95207.b4","volume":"66","author":"M Kubo","year":"2006","unstructured":"Kubo M, Kiyohara Y, Ninomiya T, Tanizaki Y, Yonemoto K, Doi Y, et al. Decreasing incidence of lacunar vs other types of cerebral infarction in a Japanese population. Neurology. 2006;66:1539\u201344. https:\/\/doi.org\/10.1212\/01.wnl.0000216132.95207.b4.","journal-title":"Neurology"},{"key":"453_CR3","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","volume":"6","author":"T Furugohri","year":"2008","unstructured":"Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo Pharmacological profiles. J Thromb Haemost. 2008;6:1542\u20139. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.03064.x.","journal-title":"J Thromb Haemost"},{"key":"453_CR4","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"key":"453_CR5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jth.12230","volume":"11","author":"G Raskob","year":"2013","unstructured":"Raskob G, B\u00fcller H, Prins M, Segers A, Shi M, Schwocho L, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study\u2013methodological implications for clinical trials. J Thromb Haemost. 2013;11:1287\u201394. https:\/\/doi.org\/10.1111\/jth.12230.","journal-title":"J Thromb Haemost"},{"key":"453_CR6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/j.1365-2125.2012.04409.x","volume":"75","author":"J Mendell","year":"2013","unstructured":"Mendell J, Noveck RJ, Shi M. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of Edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol. 2013;75:966\u201378. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04409.x.","journal-title":"Br J Clin Pharmacol"},{"key":"453_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","volume":"55","author":"DA Parasrampuria","year":"2016","unstructured":"Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of Edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55:641\u201355. https:\/\/doi.org\/10.1007\/s40262-015-0342-7.","journal-title":"Clin Pharmacokinet"},{"key":"453_CR8","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00228-014-1736-4","volume":"70","author":"OQ Yin","year":"2014","unstructured":"Yin OQ, Kimura T, Miller R. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol. 2014;70:1339\u201351. https:\/\/doi.org\/10.1007\/s00228-014-1736-4.","journal-title":"Eur J Clin Pharmacol"},{"key":"453_CR9","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","volume":"385","author":"CT Ruff","year":"2015","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between Edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385:2288\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(14)61943-7.","journal-title":"Lancet"},{"key":"453_CR10","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","volume":"40","author":"TF Chao","year":"2049","unstructured":"Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, et al. Clinical outcomes, Edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2049;40:1518\u201327. https:\/\/doi.org\/10.1093\/eurheartj\/ehy807.","journal-title":"Eur Heart J"},{"key":"453_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1124\/dmd.113.054866","volume":"42","author":"T Mikkaichi","year":"2014","unstructured":"Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug\u2019s disposition. Drug Metab Dispos. 2014;42:520\u20138. https:\/\/doi.org\/10.1124\/dmd.113.054866.","journal-title":"Drug Metab Dispos"},{"key":"453_CR12","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1124\/dmd.112.046888","volume":"40","author":"MS Bathala","year":"2012","unstructured":"Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of Edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40:2250\u20135. https:\/\/doi.org\/10.1124\/dmd.112.046888.","journal-title":"Drug Metab Dispos"},{"key":"453_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/FPC.0000000000000294","volume":"27","author":"S Ueshima","year":"2017","unstructured":"Ueshima S, Hira D, Fujii R, Kimura Y, Tomitsuka C, Yamane T, et al. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of Apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017;27:329\u201336. https:\/\/doi.org\/10.1097\/FPC.0000000000000294.","journal-title":"Pharmacogenet Genomics"},{"key":"453_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PGPM.S157111","volume":"11","author":"AV Kryukov","year":"2018","unstructured":"Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of Apixaban in patients with atrial fibrillation and acute stroke. Pharmgenomics Pers Med. 2018;11:43\u20139. https:\/\/doi.org\/10.2147\/PGPM.S157111.","journal-title":"Pharmgenomics Pers Med"},{"key":"453_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00228-019-02639-8","volume":"75","author":"J Zdovc","year":"2049","unstructured":"Zdovc J, Petre M, Pi\u0161lar M, Repnik K, Mrhar A, Vogrin M, et al. Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of Rivaroxaban: A population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2049;75:817\u201324. https:\/\/doi.org\/10.1007\/s00228-019-02639-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"453_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bcpt.13488","volume":"128","author":"J Nakagawa","year":"2021","unstructured":"Nakagawa J, Kinjo T, Iizuka M, Ueno K, Tomita H, Niioka T. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of Rivaroxaban in patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2021;128:297\u2013304. https:\/\/doi.org\/10.1111\/bcpt.13488.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"453_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/tpj.2016.82","volume":"18","author":"AG Vandell","year":"2018","unstructured":"Vandell AG, Lee J, Shi M, Rubets I, Brown KS, Walker JR. An integrated Pharmacokinetic\/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on Edoxaban exposure. Pharmacogenomics J. 2018;18:153\u20139. https:\/\/doi.org\/10.1038\/tpj.2016.82.","journal-title":"Pharmacogenomics J"},{"key":"453_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/FTD.0000000000001042","volume":"45","author":"J Nakagawa","year":"2023","unstructured":"Nakagawa J, Kinjo T, Aiuchi N, Ueno K, Tomita H, Niioka T. Associations among plasma concentrations of Edoxaban and M-4, prothrombin time, and the SLCO1B1*15 haplotype in patients with non-valvular atrial fibrillation. Ther Drug Monit. 2023;45:409\u201316. https:\/\/doi.org\/10.1097\/FTD.0000000000001042.","journal-title":"Ther Drug Monit"},{"key":"453_CR19","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/jcph.306","volume":"54","author":"S Song","year":"2014","unstructured":"Song S, Kang D, Halim AB, Miller R. Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from Edoxaban treatment. J Clin Pharmacol. 2014;54:910\u20136. https:\/\/doi.org\/10.1002\/jcph.306.","journal-title":"J Clin Pharmacol"},{"key":"453_CR20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/jcph.541","volume":"55","author":"S J\u00f6nsson","year":"2015","unstructured":"J\u00f6nsson S, Simonsson US, Miller R, Karlsson MO. Population pharmacokinetics of Edoxaban and its main metabolite in a dedicated renal impairment study. J Clin Pharmacol. 2015;55:1268\u201379. https:\/\/doi.org\/10.1002\/jcph.541.","journal-title":"J Clin Pharmacol"},{"key":"453_CR21","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/bcp.12727","volume":"80","author":"R Niebecker","year":"2015","unstructured":"Niebecker R, J\u00f6nsson S, Karlsson MO, Miller R, Nyberg J, Krekels EH, et al. Population pharmacokinetics of Edoxaban in patients with symptomatic deep-vein thrombosis and\/or pulmonary embolism\u2013the Hokusai-VTE phase 3 study. Br J Clin Pharmacol. 2015;80:1374\u201387. https:\/\/doi.org\/10.1111\/bcp.12727.","journal-title":"Br J Clin Pharmacol"},{"key":"453_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40262-016-0378-3","volume":"55","author":"EH Krekels","year":"2016","unstructured":"Krekels EH, Niebecker R, Karlsson MO, Miller R, Shimizu T, Karlsson KE, et al. Population pharmacokinetics of Edoxaban in patients with Non-Valvular atrial fibrillation in the ENGAGE AF-TIMI 48 study, a phase III clinical trial. Clin Pharmacokinet. 2016;55:1079\u201390. https:\/\/doi.org\/10.1007\/s40262-016-0378-3.","journal-title":"Clin Pharmacokinet"},{"key":"453_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"453_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357. https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005.","journal-title":"Comput Methods Programs Biomed"},{"key":"453_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00007691-200502000-00005","volume":"27","author":"S Tsuchiwata","year":"2005","unstructured":"Tsuchiwata S, Mihara K, Yafune A, Ogata H. Evaluation of bayesian Estimation of Pharmacokinetic parameters. Ther Drug Monit. 2005;27:18\u201324. https:\/\/doi.org\/10.1097\/00007691-200502000-00005.","journal-title":"Ther Drug Monit"},{"key":"453_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/10543400701513975","volume":"17","author":"T Funatogawa","year":"2007","unstructured":"Funatogawa T, Funatogawa I, Yafune A. An Estimation method of the half-life for a one-compartment model of a single bolus intravenous injection by a single sampling. J Biopharm Stat. 2007;17:827\u201337. https:\/\/doi.org\/10.1080\/10543400701513975.","journal-title":"J Biopharm Stat"},{"key":"453_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/10543406.2010.502983","volume":"22","author":"T Funatogawa","year":"2012","unstructured":"Funatogawa T, Funatogawa I. An Estimation method of the clearance for a one-compartment model of a single bolus intravenous injection by a single sampling. J Biopharm Stat. 2012;22:43\u201353. https:\/\/doi.org\/10.1080\/10543406.2010.502983.","journal-title":"J Biopharm Stat"},{"key":"453_CR28","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/cpdd.53","volume":"2","author":"N Matsushima","year":"2013","unstructured":"Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and safety of the factor Xa inhibitor Edoxaban and the effects of Quinidine in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:358\u201366. https:\/\/doi.org\/10.1002\/cpdd.53.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"453_CR29","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/jcph.550","volume":"55","author":"J Mendell","year":"2015","unstructured":"Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on Edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015;55:1395\u2013405. https:\/\/doi.org\/10.1002\/jcph.550.","journal-title":"J Clin Pharmacol"},{"key":"453_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","volume":"13","author":"J Mendell","year":"2013","unstructured":"Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of Edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13:331\u201342. https:\/\/doi.org\/10.1007\/s40256-013-0029-0.","journal-title":"Am J Cardiovasc Drugs"},{"key":"453_CR31","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/bcp.13092","volume":"82","author":"DA Parasrampuria","year":"2016","unstructured":"Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016;82:1591\u2013600. https:\/\/doi.org\/10.1111\/bcp.13092.","journal-title":"Br J Clin Pharmacol"},{"key":"453_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40261-015-0298-2","volume":"35","author":"J Mendell","year":"2015","unstructured":"Mendell J, Chen S, He L, Desai M, Parasramupria AP. The effect of Rifampin on the pharmacokinetics of Edoxaban in healthy adults. Clin Drug Investig. 2015;35:447\u201353. https:\/\/doi.org\/10.1007\/s40261-015-0298-2.","journal-title":"Clin Drug Investig"},{"key":"453_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.TP.0000130981.55654.78","volume":"78","author":"L Bonhomme-Faivre","year":"2004","unstructured":"Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, et al. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation. 2004;78:21\u20135. https:\/\/doi.org\/10.1097\/01.TP.0000130981.55654.78.","journal-title":"Transplantation"},{"key":"453_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/FPC.0b013e3282f7046f","volume":"18","author":"S Crettol","year":"2008","unstructured":"Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics. 2008;18:307\u201315. https:\/\/doi.org\/10.1097\/FPC.0b013e3282f7046f.","journal-title":"Pharmacogenet Genomics"},{"key":"453_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00228-012-1355-x","volume":"69","author":"M Garc\u00eda","year":"2013","unstructured":"Garc\u00eda M, Mac\u00edas RM, Cubero JJ, Ben\u00edtez J, Caravaca F, Gervasini G. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol. 2013;69:385\u201393. https:\/\/doi.org\/10.1007\/s00228-012-1355-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"453_CR36","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockm\u00f6ller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473\u20138. https:\/\/doi.org\/10.1073\/pnas.97.7.3473.","journal-title":"Proc Natl Acad Sci USA"},{"key":"453_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1067\/mcp.2001.117412","volume":"70","author":"RB Kim","year":"2001","unstructured":"Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189\u201399. https:\/\/doi.org\/10.1067\/mcp.2001.117412.","journal-title":"Clin Pharmacol Ther"},{"key":"453_CR38","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1023\/A:1012244520615","volume":"18","author":"T Sakaeda","year":"2001","unstructured":"Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of Digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400\u20134. https:\/\/doi.org\/10.1023\/A:1012244520615.","journal-title":"Pharm Res"},{"key":"453_CR39","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1097\/01.ASN.0000073901.94759.36","volume":"14","author":"D Anglicheau","year":"2003","unstructured":"Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003;14:1889\u201396. https:\/\/doi.org\/10.1097\/01.ASN.0000073901.94759.36.","journal-title":"J Am Soc Nephrol"},{"key":"453_CR40","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2146\/ajhp080396","volume":"66","author":"L Bonhomme-Faivre","year":"2009","unstructured":"Bonhomme-Faivre L, Picard V, Saliba F, Abbara C, Fodil M, Chaunoy M, et al. Effect of the ABCB1 3435C\u2009>\u2009T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. Am J Health Syst Pharm. 2009;66:1645\u201351. https:\/\/doi.org\/10.2146\/ajhp080396.","journal-title":"Am J Health Syst Pharm"},{"key":"453_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2125.2009.03461.x","volume":"68","author":"AF Hawwa","year":"2009","unstructured":"Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, James C, McElnay JC. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol. 2009;68:413\u201321. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03461.x.","journal-title":"Br J Clin Pharmacol"},{"key":"453_CR42","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","volume":"54","author":"S Wolking","year":"2015","unstructured":"Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet. 2015;54:709\u201335. https:\/\/doi.org\/10.1007\/s40262-015-0267-1.","journal-title":"Clin Pharmacokinet"},{"key":"453_CR43","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0091270003257222","volume":"43","author":"I Mai","year":"2003","unstructured":"Mai I, St\u00f6rmer E, Goldammer M, Johne A, Kr\u00fcger H, Budde K, et al. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol. 2003;43:1101\u20137. https:\/\/doi.org\/10.1177\/0091270003257222.","journal-title":"J Clin Pharmacol"},{"key":"453_CR44","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clpt.2004.01.009","volume":"75","author":"D Anglicheau","year":"2004","unstructured":"Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther. 2004;75:422\u201333. https:\/\/doi.org\/10.1016\/j.clpt.2004.01.009.","journal-title":"Clin Pharmacol Ther"},{"key":"453_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/01.tp.0000234942.78716.c0","volume":"82","author":"S Fredericks","year":"2006","unstructured":"Fredericks S, Moreton M, Reboux S, Carter ND, Goldberg L, Holt DW, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation. 2006;82:705\u20138. https:\/\/doi.org\/10.1097\/01.tp.0000234942.78716.c0.","journal-title":"Transplantation"},{"key":"453_CR46","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1007\/s11095-009-9867-5","volume":"26","author":"K Hosohata","year":"2009","unstructured":"Hosohata K, Masuda S, Yonezawa A, Katsura T, Oike F, Ogura Y, et al. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients. Pharm Res. 2009;26:1590\u20135. https:\/\/doi.org\/10.1007\/s11095-009-9867-5.","journal-title":"Pharm Res"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00453-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00453-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00453-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:16:56Z","timestamp":1748863016000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00453-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00453-2","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Review Board of Ritsumeikan University Biwako-Kusatsu Campus (Approval number BKC-IRB-2020-025), the Ethics Boards of Shiga University of Medical Science (Approval number 29\u2013099), the Ethics Committee of Kyoto University Graduate School of Medicine (Approval number R1817). Written informed consent was obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author M.H. has partly received research promotion grants from Daiichi Sankyo Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}